← Back to patent-cliff list
PB-718
Tier C — Watch / tradePB-718
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GLP1R, GCGR
Indications (approved)：Obesity, Overweight, 先天性高胰岛素血症, Non-alcoholic steatohepatitis
Regional status
US
Phase I
2019-08-26
EU
-
China
Phase II
2023-07-06
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of PB-718?
Approved indications include: Obesity, Overweight, 先天性高胰岛素血症, Non-alcoholic steatohepatitis.
When does the PB-718 patent expire?
No public expiry year is available for PB-718 yet; this page updates once verified.
How do I get a quote for PB-718 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02